Direct validation of NGcGM3 ganglioside as a new target for cancer immunotherapy.

@article{Labrada2010DirectVO,
  title={Direct validation of NGcGM3 ganglioside as a new target for cancer immunotherapy.},
  author={Mayrel Labrada and Marilyn Clavell and Yan{\'i}n Bebelagua and J. De Windt Leon and Daniel Fernando Alonso and Mariano R Gabri and Roberto Carlos Veloso and Vicente V{\'e}rez and Luis E. Fern{\'a}ndez},
  journal={Expert opinion on biological therapy},
  year={2010},
  volume={10 2},
  pages={
          153-62
        }
}
OBJECTIVE The target concept means not only an aberrant expression of a particular molecule in tumour tissues but also evidence of a clear therapeutic advantage, as a consequence of immune-intervention, in an antigen-positive relevant tumour model. Since we reported the presence of NGcGM3 ganglioside in human breast tumours years ago and though Phase I clinical trials of a ganglioside containing vaccine have been conducted, a definitive direct validation of this peculiar molecule as target for… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 24 CITATIONS

Ganglioside as a Therapy Target in Various Types of Cancer.

  • Asian Pacific journal of cancer prevention : APJCP
  • 2016
VIEW 2 EXCERPTS
CITES BACKGROUND